Sanofi India Ltd
(BOM:500674)
₹
3,079.85
-27.15 (-0.87%)
Market Cap: 70.93 Bil
Enterprise Value: 67.34 Bil
PE Ratio: 21.91
PB Ratio: 8.59
GF Score: 78/100 
Q2 2027 Sanofi India Ltd Earnings Call Transcript
Aug 05, 2026 / 10:30AM GMT
Release Date Price:
₹3329.8
(-1.83%)
Key Points
Positve
- Sanofi India Ltd (BOM:500674) reported a strong 14% double-digit growth in Q2 2026, driven by its innovative diabetes portfolio, including Toujeo and Soliqua.
- The company's diabetes business unit achieved 17% growth in the first half of 2026, significantly outpacing the market and demonstrating successful execution of its strategic transformation.
- Sanofi India Ltd (BOM:500674) maintained a dominant market leadership in the basal insulin segment, holding a 58% value and 61% volume market share with Lantus and Toujeo combined.
- The company's partnership model with Emcure and Cipla is showing positive results, with the OAD segment meeting market growth and overall partnership business growing 2% in Q2.
- Sanofi India Ltd (BOM:500674) delivered a strong 19% growth in profit before tax for Q2, driven by operational excellence and significant cost discipline, with operating expenses down 15% in H1.
- The company's cash position grew by 34%, reflecting a very healthy financial situation and providing flexibility for future investments and shareholder returns.
- Sanofi India Ltd (BOM:500674) is expanding its public sector presence with 70% growth, securing new accounts in state and care segments for Toujeo and Soliqua.
- The company is leveraging real-world evidence and Indian patient data to strengthen its product positioning and advocacy in the diabetes market.
- Sanofi India Ltd (BOM:500674) is actively investing in digital outreach and AI-enabled platforms to reach Tier 2 and Tier 3 markets, enhancing patient support programs.
- The company's CSR initiatives are ahead of schedule, with over 600,000 direct beneficiaries expected by year-end, strengthening its community impact and brand equity.
Negative
- Sanofi India Ltd (BOM:500674) reported a 2% decline in total income for H1 2026, impacted by one-off transition costs and safety stock adjustments related to its partnership agreements.
- The partnership business for Cardiovascular and CNS products showed anemic growth of only 2% in Q2, below industry expectations, with management not expecting to reach industry growth until 2027.
- Export business faced challenges, particularly in the Australian market due to intense competition for mature products, leading to a 2% decline in export sales.
- The company's overall sales declined 2% in H1 2026, with the partnership segment still in a transition phase and not yet delivering expected growth.
- Sanofi India Ltd (BOM:500674) faces potential competitive pressure from new once-weekly insulin entrants, which could impact the growth trajectory of its once-daily products like Toujeo and Lantus.
- The company's other operating income declined due to reduced services provided to consumer health entities, impacting overall revenue growth.
- Management acknowledged that the partnership business is not meeting expectations and requires significant reorganization and reinvestment from partners to improve performance.
- The company's growth is heavily reliant on the diabetes segment, with limited visibility on new product launches or diversification into other therapeutic areas in the near term.
- Sanofi India Ltd (BOM:500674) is not expecting to reach industry-level growth in the partnership portfolio during 2026, indicating prolonged underperformance in this segment.
- The company's dividend payout ratio remains uncertain, with management unable to commit to maintaining historical payout levels, potentially disappointing income-focused investors.
Operator
(audio in progress) -- Limited. Before you go, there are [team] important announcements, please note that the proceedings of this meeting are recorded.
Secondly, please note a standard disclaimer that there are certain statements in this call which may be forward-looking and the actual results may vary depending on the various other factors which may impact the future performance.
Moving on to the agenda, we will cover the performance for the quarter and half-year ended June 2026 and other highlights. Thereafter, we will have a Q&A session which will end at exactly sharp 5:00 P M. All investors and participants are please requested to keep the questions brief and to avoid any repetition. (Operator Instructions)
I now hand over the proceedings to the management to take us through the presentation.
Deepak Arora
Sanofi India Ltd - Managing Director, Additional Director
Thank you so much and a very good evening to everyone. I'm very excited and delighted to share the domestic results of quarter two, 2026. On behalf of the India
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers